Related Experiment Video
Updated: Aug 22, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Role of genetic testing in young patients with idiopathic atrioventricular conduction disease
Angelo Auricchio1, Andrea Demarchi1, Tardu Özkartal1,2
1Division of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano 6900, Switzerland.
Insights
Genetic testing aids diagnosis in young patients with idiopathic atrioventricular block (AVB) requiring pacemaker implantation. This rare condition, affecting individuals under 50, can be diagnosed in up to 20% of cases through genetic analysis and ajmaline challenge.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Idiopathic atrioventricular block (AVB) requiring pacemaker implantation before age 50 is a rare condition.
- The underlying causes of AVB in young adults are often unknown, necessitating further investigation.
Purpose of the Study:
- To evaluate the role and diagnostic yield of genetic testing in patients under 50 years old with idiopathic AVB.
- To identify potential genetic variants associated with this rare cardiac condition.
Main Methods:
- Retrospective analysis of pacemaker implantations in Southern Switzerland (2010-2019).
- Inclusion criteria: age < 50 years and AVB of unknown etiology.
- Genetic testing using a next-generation sequencing panel (174 genes) and Sanger sequencing.
- Ajmaline challenge and echocardiographic assessment were performed.
Main Results:
- 15 patients (0.6%) met the inclusion criteria, with a median age of 44 years.
- Genetic findings (pathogenic variants or VUS) were present in 67% of patients.
- A TRPM4 gene variant (c.2531G > A p.(Gly844Asp)) was identified in 20% of unrelated patients.
- Specific diagnoses like Brugada syndrome and long-QT syndrome were established in 13% of cases.
Conclusions:
- Idiopathic AVB in young adults is rare, with an incidence of 0.7 per 100,000 person-years.
- Systematic investigation, including genetic testing, can diagnose specific conditions in up to 20% of these patients.
- The TRPM4 variant warrants further investigation for its potential association with idiopathic AVB.
Aims:
To investigate the role of genetic testing in patients with idiopathic atrioventricular conduction disease requiring pacemaker (PM) implantation before the age of 50 years.
Methods And Results:
All consecutive PM implantations in Southern Switzerland between 2010 and 2019 were evaluated. Inclusion criteria were: (i) age at the time of PM implantation: < 50 years; (ii) atrioventricular block (AVB) of unknown aetiology. Study population was investigated by ajmaline challenge and echocardiographic assessment over time. Genetic testing was performed using next-generation sequencing panel, containing 174 genes associated to inherited cardiac diseases, and Sanger sequencing confirmation of suspected variants with clinical implication. Of 2510 patients who underwent PM implantation, 15 (0.6%) were young adults (median age: 44 years, male predominance) presenting with advanced AVB of unknown origin. The average incidence of idiopathic AVB computed over the 2010-2019 time window was 0.7 per 100 000 persons per year (95% CI 0.4-1.2). Most of patients (67%) presented with specific genetic findings (pathogenic variant) or variants of uncertain significance (VUS). A pathogenic variant of PKP2 gene was found in one patient (6.7%) with no overt structural cardiac abnormalities. A VUS of TRPM4, MYBPC3, SCN5A, KCNE1, LMNA, GJA5 genes was found in other nine cases (60%). Of these, three unrelated patients (20%) presented the same heterozygous missense variant c.2531G > A p.(Gly844Asp) in TRPM4 gene. Diagnostic re-assessment over time led to a diagnosis of Brugada syndrome and long-QT syndrome in two patients (13%). No cardiac events occurred during a median follow-up of 72 months.
Conclusion:
Idiopathic AVB in adults younger than 50 years is a very rare condition with an incidence of 0.7 per 100 000 persons/year. Systematic investigations, including genetic testing and ajmaline challenge, can lead to the achievement of a specific diagnosis in up to 20% of patients. Heterozygous missense variant c.2531G > A p.(Gly844Asp) in TRPM4 gene was found in an additional 20% of unrelated patients, suggesting possible association of the variant with the disease.
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Dysrhythmias V: Evaluating Dysrhythmias
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Myocarditis II: Clinical Features and Diagnostic Tests

